Oscar Health

Oscar Health’s stock climbed to a 52-week high of $33.12 and has a market capitalization of $10.17 billion and a P/E ratio of 17.27. Year-to-date the share price is up 110.1%, up 114% since the start of the year, and up 129% over six months. In the second quarter Oscar Health beat expectations with adjusted earnings per share of $1.10 and revenue of $4.88 billion; the company attributes the results to record profitability, improved medical cost trends and tighter cost control. An analysis by InvestingPro currently rates the stock as overvalued. » More on de.investing.com

Oscar Health reported $1 billion net income in the first half of 2026, citing disciplined pricing, operating leverage and AI tools (Oswell) that guided members to lower-cost care and identified pharmacy savings. Management raised full-year 2026 earnings from operations guidance to $500 million–$700 million and expects full-year MLR of 81.5%–82.5%, while forecasting higher churn in H2 as CMS eligibility verifications accelerate. Company noted a $160 million favorable 2025 risk-adjustment true-up, continued SG&A efficiency from its single-platform tech stack, and ongoing CMS reviews with anticipated impacts already reflected in guidance. » More on finance.yahoo.com

Oscar Health reported a $361.8 million second-quarter profit and $1.04 billion in net income for the first half of 2026, driven by revenue growth to $4.9 billion and an increase in health plan members to 2.9 million. The company credited disciplined pricing, scalable technology and $164 million of favorable prior-period reserve development for a lower medical loss ratio of 79.2%, down from 91.1% year over year. CEO Mark Bertolini said Oscar is positioned for continued profitable growth in the Affordable Care Act individual market and raised its full-year outlook on several metrics. » More on forbes.com